Cargando…

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

PURPOSE: To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. PATIENTS AND METHODS: PREVAIL...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huafang, Li, Yan, Feng, Yu, Zhuo, Jianmin, Turkoz, Ibrahim, Mathews, Maju, Tan, Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927347/
https://www.ncbi.nlm.nih.gov/pubmed/29731633
http://dx.doi.org/10.2147/NDT.S157399
_version_ 1783319072021151744
author Li, Huafang
Li, Yan
Feng, Yu
Zhuo, Jianmin
Turkoz, Ibrahim
Mathews, Maju
Tan, Wilson
author_facet Li, Huafang
Li, Yan
Feng, Yu
Zhuo, Jianmin
Turkoz, Ibrahim
Mathews, Maju
Tan, Wilson
author_sort Li, Huafang
collection PubMed
description PURPOSE: To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. PATIENTS AND METHODS: PREVAIL was a multicenter, single-arm, open-label, prospective Phase IV study in hospitalized Asian patients (either sex, aged 18–65 years) diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition). Change from baseline to week 13 in primary (Positive and Negative Syndrome Scale [PANSS] total score), secondary endpoints (PANSS responder rate, PANSS subscale, PANSS Marder factor, Clinical Global Impression-Severity, and Personal and Social Performance scale scores, readiness for hospital discharge questionnaire) and safety were assessed in this post hoc analysis. RESULTS: Significant mean reduction from baseline to week 13 in the PANSS total score, 30% PANSS responder rates (P≤0.01), PANSS subscales (positive and general psychopathology; all P≤0.01), PANSS Marder factor (positive symptoms, uncontrolled hostility, and excitement and anxiety/depression; all P≤0.01), Personal and Social Performance scale scores (P≤0.05) and Clinical Global Impression-Severity categorical summary (P≤0.05) were significantly greater in the ≤1 week subgroup versus >1 week subgroup (P≤0.05). The readiness for hospital discharge questionnaire improved over time for the overall study population, but remained similar between subgroups at all-time points. Treatment-emergent adverse events were similar between the subgroups. CONCLUSION: Early initiation of once-monthly paliperidone palmitate in hospitalized patients with acute exacerbation of schizophrenia led to greater improvements in psychotic symptoms with comparable safety than treatment initiation following 1 week of hospitalization.
format Online
Article
Text
id pubmed-5927347
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59273472018-05-04 Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study Li, Huafang Li, Yan Feng, Yu Zhuo, Jianmin Turkoz, Ibrahim Mathews, Maju Tan, Wilson Neuropsychiatr Dis Treat Original Research PURPOSE: To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. PATIENTS AND METHODS: PREVAIL was a multicenter, single-arm, open-label, prospective Phase IV study in hospitalized Asian patients (either sex, aged 18–65 years) diagnosed with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition). Change from baseline to week 13 in primary (Positive and Negative Syndrome Scale [PANSS] total score), secondary endpoints (PANSS responder rate, PANSS subscale, PANSS Marder factor, Clinical Global Impression-Severity, and Personal and Social Performance scale scores, readiness for hospital discharge questionnaire) and safety were assessed in this post hoc analysis. RESULTS: Significant mean reduction from baseline to week 13 in the PANSS total score, 30% PANSS responder rates (P≤0.01), PANSS subscales (positive and general psychopathology; all P≤0.01), PANSS Marder factor (positive symptoms, uncontrolled hostility, and excitement and anxiety/depression; all P≤0.01), Personal and Social Performance scale scores (P≤0.05) and Clinical Global Impression-Severity categorical summary (P≤0.05) were significantly greater in the ≤1 week subgroup versus >1 week subgroup (P≤0.05). The readiness for hospital discharge questionnaire improved over time for the overall study population, but remained similar between subgroups at all-time points. Treatment-emergent adverse events were similar between the subgroups. CONCLUSION: Early initiation of once-monthly paliperidone palmitate in hospitalized patients with acute exacerbation of schizophrenia led to greater improvements in psychotic symptoms with comparable safety than treatment initiation following 1 week of hospitalization. Dove Medical Press 2018-04-26 /pmc/articles/PMC5927347/ /pubmed/29731633 http://dx.doi.org/10.2147/NDT.S157399 Text en © 2018 Li et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Li, Huafang
Li, Yan
Feng, Yu
Zhuo, Jianmin
Turkoz, Ibrahim
Mathews, Maju
Tan, Wilson
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title_full Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title_fullStr Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title_full_unstemmed Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title_short Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
title_sort impact of time of initiation of once-monthly paliperidone palmitate in hospitalized asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the prevail study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927347/
https://www.ncbi.nlm.nih.gov/pubmed/29731633
http://dx.doi.org/10.2147/NDT.S157399
work_keys_str_mv AT lihuafang impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT liyan impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT fengyu impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT zhuojianmin impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT turkozibrahim impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT mathewsmaju impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy
AT tanwilson impactoftimeofinitiationofoncemonthlypaliperidonepalmitateinhospitalizedasianpatientswithacuteexacerbationofschizophreniaaposthocanalysisfromtheprevailstudy